RIP (D94C12) XP® Rabbit mAb detects endogenous levels of total RIP (RIP1) protein. It has not been shown to cross-react with other RIP family members.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu190 of human RIP.
Background
The RIP (receptor-interacting protein) family of serine-threonine kinases (RIP, RIP2, RIP3 and RIP4) are important regulators of cellular stress that can trigger pro-survival and inflammatory responses through the activation of NF-κB as well as pro-apoptotic pathways (1). In addition to the kinase domain, RIP contains a death domain responsible for interaction with the death domain receptor Fas and for the recruitment to TNFR1 through interaction with TRADD (2,3). RIP also interacts with TNF-receptor-associated factors (TRAFs) and can recruit IKKs to the TNFR1 signaling complex via interaction with NEMO leading to IκB phosphorylation and degradation (6,7). Overexpression of RIP induces both NF-κB activation and apoptosis (2,3). Caspase-8 dependent cleavage of the death domain on RIP can trigger the apoptotic activity of RIP (8). RIP-deficient cells show a failure in TNF-mediated NF-κB activation making the cells more sensitive to apoptosis (4,5).
Storage:Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.